Replies to post #41 on Regeneron Pharmaceuticals Inc (REGN)

[surf1944]

6:40AM Regeneron Pharms beats by $0.45, beats on revs (REGN) 121.44 : Reports Q2 (Jun) earnings of $0.90 per share, $0.45 better than the Capital IQ Consensus Estimate of $0.45; revenues rose 181.5% year/year to $304 mln vs the $255.08 mln consensus. Non-GAAP net income excludes non-cash share-based compensation expense and non-cash interest expense related to the Company's convertible senior notes. "Based on the results to date, we now forecast 2012 U.S. EYLEA net product sales of $700 to $750 million and expect to be profitable for the full year. We look forward to marketing approvals and launch of EYLEA outside the U.S. by our collaborator, Bayer HealthCare (BAYRY), during the second half of the year. We also await the September 23, 2012 PDUFA date for an FDA decision on our application to market EYLEA in the U.S. for the treatment of central retinal vein occlusion (CRVO), which would be in addition to our already approved EYLEA indication in the U.S. for neovascular age-related macular degeneration (wet AMD)."